Toxic Megacolon

Back

Background

Toxic megacolon is a life-threatening condition characterized by nonobstructive segmental or pancolonic dilatation of at least 6 cm with systemic toxicity.[1] It was recognized by Marshak and Lester in 1950.[2] Although inflammatory bowel disease (IBD) is a common reason for toxic megacolon, other etiologies including infections, inflammation, bowel ischemia, radiation, and certain medications can lead to the development of this condition.[3, 4, 5] See the following images.



View Image

Toxic Megacolon. A 22-year-old man presented with abdominal pain, passage of blood and mucus per rectum, abdominal distention, fever, and disorientati....



View Image

Toxic Megacolon. Gross pathology specimen from a case of pseudomembranous colitis demonstrating characteristic yellowish plaques.



View Image

Toxic Megacolon. Computed tomography scan from a patient with pseudomembranous colitis demonstrating the classic accordion sign.

It is important to differentiate toxic megacolon from other conditions that present with megacolon without systemic toxicity such as Hirschsprung disease,[6] idiopathic megacolon/chronic constipation, chronic long-standing constipation of any etiology, and intestinal pseudo-obstruction (Ogilvie syndrome).[1]  Patients with these conditions do not develop signs of systemic toxicity and, therefore, do not fall into the category of having toxic megacolon (see the image below). (See also Etiology, Presentation, and Workup.)



View Image

Toxic Megacolon. A 72-year-old woman presented with vomiting and abdominal distention. The supine (right) and erect (left) plain abdominal radiographs....

Pathophysiology

Although the precise pathophysiology of toxic megacolon is unproven, several factors may contribute to its development and precipitation. In cases of uncomplicated colitis, the inflammatory response is confined to the mucosa. The microscopic hallmark of toxic megacolon is inflammation extending beyond the mucosa into the muscularis propria. Whereas the typical ulcerative colitis inflammatory response is limited to the mucosa, toxic megacolon is characterized by severe inflammation extending into the smooth muscle layer, thus paralyzing the colonic smooth muscle and leading to dilatation. The extent of dilatation seems to be correlated with the depth of inflammation and ulceration.[1]

Studies by Mourelle et al showed significantly increased amounts of inducible nitric oxide (NO) synthetase in the muscularis propria of patients with toxic megacolon, particularly in the more dilated colonic segments.[7, 8, 9]

As inflammation progresses into the smooth-muscle layers of the colon, NO and local inflammatory modulators appear to be involved in toxic megacolon pathogenesis. Neutrophils invade the muscle layer in toxic megacolon and directly damage the myocytes by the release of proteolytic enzymes, cytokines, and leukotriene B4. Systemic uptake of cytokines and other inflammatory mediators leads to fever, tachycardia, hypotension, and other signs of systemic toxicity. NO is generated by macrophages and smooth muscles cells in the inflamed portions of the colon, inhibiting smooth muscle tone and leading to colonic dilatation.[1]

These findings were supported by the idea that, in animal models, giving dexamethasone and/or decontaminating the bowel with broad-spectrum antibiotics led to decreased NO levels and improvement in colonic dilatation.[8] According to a study by Schworer et al, patients with toxic megacolon were successfully treated with NO synthase inhibitor.[10]

A number of other precipitating factors have been identified, including antimotility agents, opiates, anticholinergics, antidepressants, barium enemas, colonoscopies/bowel preparations, and immunotherapies.[5, 11, 12]

Myenteric plexus involvement is not consistent and likely does not contribute to colonic dilatation.

Etiology

Inflammatory causes of toxic megacolon include the following:

Infectious causes of toxic megacolon include the following:

Other etiologies of toxic megacolon include the following:

Often, triggering or predisposing factors can be identified. Signs and symptoms of acute colitis may be present for as long as 1 week before dilatation develops. Although the risk of toxic megacolon increases with the severity of the colitis, rapid tapering or abrupt discontinuation of medications such as steroids, sulfasalazine, and 5-aminosalicylic acid may precipitate toxemia and dilatation.

Medications that negatively impact bowel motility are also implicated in the development of toxic megacolon. These include, but are not limited to, anticholinergics, antidepressants, loperamide, atropine,[5] and opioids. Procedures such as barium enema or colonoscopy may cause distention, impair blood supply, or exacerbate a microperforation and cause subsequent toxemia.[12]

A retrospective study by Tschudin-Sutter et al indicated that the incidence of toxic megacolon is higher in pediatric patients with community–associated, rather than healthcare facility–associated, C difficile infection.[33] The study involved 202 pediatric patients with C difficile infection, including 38 with community–associated infection, 144 with healthcare facility–associated infection, and 20 with an indeterminate source of infection. Compared with the healthcare facility–associated group, children with a community–associated infection had a higher rate not only of toxic megacolon but also of toxic shock and recurrence. (They were less likely, however, to have comorbidities than were children with healthcare facility–associated infection.)[33]

Epidemiology

There is a lack in literature regarding accurate reporting of toxic megacolon prevalence. The incidence rates can change based on the main etiology. The risk of developing toxic megacolon can increase with older age and/or the presence of other risk factors such as hypertension, neurologic disorders, coagulopathy, anemia, chronic pulmonary disease, congestive heart failure, and renal failure.[34, 35]

Doshi et al reported the results of an analysis of data collected from the Nationwide Inpatient Sample database from January 2010 through December 2014: The most common cause of hospital admissions was inflammatory bowel disease (IBD) (51.6%), followed by septicemia (10.2%) and intestinal infections (4.1%).[34, 36]

Three decades ago, the incidence of toxic megacolon in IBD patients was approximately 1-5%.[14] However, this rate has diminished due to early recognition and intensive medical management of severe colitis. Unfortunately, the data on the incidence of toxic megacolon in ulcerative colitis versus Crohn disease are contradicting; some studies show a higher incidence in patients with Crohn disease compared to those with ulcerative colitis (1-2.5% ulcerative colitis; 4.4-6.3% Crohn disease),[14] whereas others report the opposite.[4, 37]

The incidence of toxic megacolon in patients with C difficile colitis rapidly increased from 0.4% to 3% before 1990 to 4.3% after 1990, due to the rising use of broad spectrum antibiotics and the development of a hypervirulent Crohn disease strain.[4, 35, 37]

Prognosis

Toxic megacolon mortality is variable depending on the treatment modality. One study revealed that before 1976, there was a 27% mortality of toxic megacolon among patients treated medically and a 19% mortality in patients treated surgically.[38] In-hospital mortality for patients with toxic megacolon fell from 9.2% to 6.5%, according to an observational study for the period between 2010 and 2014.[35] Older age, hypertension, neurologic disorders, coagulopathy, anemia, chronic lung disease, heart failure, and renal failure were the main predictors of increased mortality.[35]

Colon perforation is associated with higher surgical mortality relative to undergoing surgery before colonic perforation.[34, 38]  Similarly, postoperative mortality in patients with C difficile infection and toxicity is lower when they undergo surgery before the development of septic shock compared to septic patients who have surgery.[39]

Fecal microbiota transplantation has shown promise as a salvage therapy for critically ill patients with C difficile infection and toxic megacolon in whom maximum medical therapy failed and who are not a surgical candidates.[40]

Mortality in patients with inflammatory bowel disease (IBD) and toxic megacolon have fallen in the last 3 decades due to multiple factors, including early recognition of toxic megacolon, early escalation from steroid treatment to biologics such as infliximab or cyclosporine, improved care in the intensive care unit (ICU), earlier surgical intervention, and optimal postoperative care.[41]

Note that C difficile infection in patients with IBD are associated with higher rates of colectomy and longer hospital stays compared to IBD patients without C difficile infection.[42]

Patient Education

Educating patients about toxic megacolon, is crucial. First, educate the patient about the causes of the disease, of which the most common is inflammatory bowel disease (IBD). However, with the rising incidence of C difficile infections, pseudomembranous colitis must always be considered, even in patients with IBD. Educate patients about ulcerative colitis, Crohn disease, and indeterminate colitis.

Also discuss with patients that medications such as corticosteroids, immunosuppressants, and/or immunomodulators may be administered to control the disease severity and that antibiotics may be used to prevent or treat infection. Inform patients of the potential risks and benefits of these agents as well as those that can exacerbate their condition (eg, opioids, antidepressants, nonsteroidal anti-inflammatories, antidiarrheals, anticholinergics.)

Secondly, clearly inform patients that if an operation is required for this acute problem, an ostomy likely will be the necessary procedure, regardless of the cause. Patients require at least a temporary and, possibly, a permanent ostomy. Provide a thoughtful, compassionate discussion regarding this aspect of their treatment: The psychological aspects of dealing with an ostomy can be extremely difficult.

Finally, educate patients so that they understand that this disease may require several months to overcome if an operation is needed and that a two- or three-stage procedure is usually required.

History

Patients with inflammatory bowel disease (IBD) are at a higher risk of developing toxic megacolon during the early stages of their disease; in some cases, it can be the first manifestation of the disease.[43, 44] Patients with Crohn colitis are more vulnerable than those with ulcerative colitis for developing toxic megacolon.[14]

Findings of ileus may indicate the severity of colitis in patients with C difficile infection.[45]

Patients with toxic megacolon typically have signs and symptoms of acute colitis that may be refractory to treatment. Common complaints include diarrhea, abdominal pain, rectal bleeding, tenesmus, vomiting, and fever. In a paper that studied the clinical presentation of pseudomembranous enterocolitis complicated with toxic megacolon, the presenting symptoms and signs included diarrhea (100%), malaise (91%), abdominal pain (82%), abdominal distention (82%), and abdominal tenderness (72%).[46] However, another study revealed that absence of diarrhea does not rule out the severity of the C difficile infections and the risk of developing toxic megacolon.[47]

A careful history may reveal recent travel, antibiotic use, chemotherapy, occupational exposure, or immunosuppression. Patients are usually very ill, and they can present with signs of fever, tachycardia, hypotension, and/or abdominal distention and tenderness.

Physical Examination

The vital signs in a patient with toxic megacolon generally reveal tachycardia and fever. If the condition is severe, the patient may be hypotensive or tachypneic; patients may be obtunded.

In inflammatory colitides (ie, ulcerative colitis, Crohn colitis), physical findings may be minimal, because high-dose steroids are routinely administered; however, the abdomen may be distended, and the bowel sounds are usually hypoactive. Signs of perforation may also be masked by high-dose steroids.

Peritoneal signs may indicate perforation. They include the following:

Approach Considerations

In general, toxic megacolon should be suspected in patients presenting with abdominal pain with distention and acute-onset chronic diarrhea. The diagnosis is made based on the clinical picture of systemic toxicity along with evidence of colon dilatation more than 6 cm.[4]

The most common criteria used to diagnose toxic megacolon are the ones proposed by Jalan et al in 1969,[43] as follows:

Complete blood cell (CBC) count 

Patients with toxic megacolon may develop leukocytosis with a left shift. Patients can also present with leukemoid reaction. Additionally, bloody diarrhea results in anemia.

Although the presence of an increased white blood cell (WBC) count contributes to the diagnosis of toxic megacolon—and most investigators believe that the absence of a high WBC count makes defining a disease as toxic megacolon difficult—an abnormally low count, or even a WBC count that is within normal limits, does not rule out toxic megacolon. This is because in immunosuppressed or extremely toxic patients, the WBC count actually may be normal or low.

Chemistry panel

Electrolyte disturbances are very common in toxic megacolon secondary to inflammatory diarrhea, steroid use, and ongoing gastrointestinal losses. The inflamed colon is unable to reabsorb salt and water. Acid-base disorders have been described (eg, metabolic alkalosis) with the large volume loss.[48] Metabolic acidosis can occur with advanced disease and the development of bowel ischemia.

Nutrition and coagulation panels

A coagulation panel should be ordered in the event that surgery is required. A nutrition panel, in accordance with the physician's practice, is helpful in assessing the patient's nutritional status. Hypoalbuminemia is common at the later stages of the disease due to protein wasting, decreased hepatic production, and severe inflammation.

ESR and CRP

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels are usually elevated. Although these findings are not specific to toxic megacolon, they may support the diagnosis.

Histology

Pathology in cases of toxic megacolon demonstrates acute inflammation involving all layers of the colon. Variable amounts of necrosis and degeneration are present. Infiltration by inflammatory cells (neutrophils, macrophages, and lymphocytes) is noted. The myenteric and submucosal plexuses are usually preserved.

Stool studies

Stool cultures, examination for ova and parasites (O&P), and as well as testing for C difficile toxin should be obtained.

Radiography

Plain abdominal radiographs are essential for the diagnosis and management of toxic megacolon. Repeated serial abdominal plain films are necessary to monitor the progress of the disease and the efficacy of treatment.

Radiographic findings include the following:

Comparison with old baseline films, if available, is helpful. Avoid barium enema studies in a patient who is severely toxic; the potential for perforation is considerable.

The following image depicts a dilated (>6 cm) transverse colon.



View Image

Toxic Megacolon. A 22-year-old man presented with abdominal pain, passage of blood and mucus per rectum, abdominal distention, fever, and disorientati....

Loss of colonic haustrations, possible "thumbprinting," is shown below



View Image

Toxic Megacolon. Plain abdominal radiograph from a patient with known ulcerative colitis who presented with an acute exacerbation of his symptoms. Thi....

Severe dilatation and a featureless transverse and sigmoid colon are demonstrated in the following image.



View Image

Toxic Megacolon. A 45-year-old woman presented with acute pain and colitis of uncertain etiology. The radiograph shows an increase in gaseous distenti....

Ultrasonography

Ultrasonography of the intestines appears to be a potential diagnostic test for toxic megacolon.[50]  In one study, investigators demonstrated similar findings in four cases, including the following:

Computed Tomography Scanning

Computed tomography (CT) scanning should be obtained in patients in whom the diagnosis of toxic megacolon is being considered. This imaging modality may identify a local or contained perforation.[4] If the diagnosis remains unclear or the cause of toxicity is thought to be an abscess, CT scanning may be helpful.

Imbriaco and Balthazar found that CT scanning was more accurate than plain radiography in detecting severe colitis.[51] CT scans may show diffuse colonic wall thickening, thickened haustra with alternating bands of high and low density (‘‘accordion sign’’), a multilayered appearance caused by different densities of edematous submucosa, or hyperemic mucosa (‘‘target sign") and peri colic stranding. CT scanning was superior in showing the severity and length of colitis as well as the presence of dilatation.[51]



View Image

Toxic Megacolon. Computed tomography scan from a patient with pseudomembranous colitis demonstrating the classic accordion sign.

Endoscopy

Endoscopy can provide a further advantage for evaluating the etiology of toxic megacolon such as identifying cytomegalovirus (CMV) or pseudomembranous colitis, especially when clinical suspicion exists despite negative stool studies for C difficile.

Endoscopy may take the form of flexible sigmoidoscopy or colonoscopy. However, if clinical concern for toxic megacolon exists, the examination should not progress beyond the sigmoid colon, if at all. The scope should be advanced only as far as necessary for diagnosis. Air insufflation should be minimal. Sigmoidoscopy can miss the diagnosis of CMV infection because the lesions can be localized in the cecum or ascending colon.[52]

According to some experts, colonoscopy is generally justified only if the patient has no or minimal inflammation of the sigmoid colon or rectum. Perforation is an obvious potential complication of this approach.[12]

Approach Considerations

The main goal of treatment for toxic megacolon is to control the severity of the colitis and to restore the colon function as soon as possible to avoid further complications, including colon perforation, dehydration, and electrolyte derangements. The initial plan and management should be coordinated between the medical and surgical teams.

Electrolyte abnormalities, especially hypokalemia as well as dehydration and anemia, must be addressed aggressively as they may exacerbate the colon dilatation. Cessation of medications that impact colonic motility, including opioids, anticholinergics, and antidiarrheals, is important.[4]

Bowel rest is recommended. Total parenteral nutrition (TPN) has not been shown to improve outcomes regarding reducing the need for surgery or decreasing hospital stay in patients with severe colitis secondary to ulcerative colitis.[53]  Placement of a nasogastric tube (NGT) is recommended to relieve upper gastrointestinaI distention, but it will not help with the colon dilatation. Some authors suggest repositioning the patient to decompress the colon by moving the air to the descending colon and rectum; these techniques include rolling maneuvers[54] and a prone knee-elbow position.[55]

Patients with severe colitis, especially those with a history of inflammatory bowel disease (IBD), carry higher risk for deep vein thrombosis (DVT); thus, DVT prophylaxis is recommended.

Broad-spectrum antibiotics are also recommended to decrease the risk of septic complications.

Enteral feeding should be started as soon as the patient shows clinical improvement to expedite mucosal healing and improve motility.

Medical Care

Inflammatory bowel disease (IBD)

Acute severe ulcerative colitis is defined as the presence of six or more bowel movements daily with at least one sign of systemic toxicity, including tachycardia, fever, anemia with hemoglobin less than 10.5 g/dL, or elevated inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Admission to the hospital for inpatient management is recommended for patients with acute severe ulcerative colitis.

Diagnostics

Stool studies are recommended, including testing for C difficile, for every patient admitted with acute severe ulcerative colitis. In one case series, up to 47% of hospitalized patients with ulcerative colitis were diagnosed with C difficile infection.[42]

Endoscopic evaluation can identify the severity of inflammation as well as establish the diagnosis at the patient's initial presentation; it can be used to obtain biopsies; and it can rule out cytomegalovirus (CMV) colitis.[56]

Complete colonoscopy can increase the risk of complications, especially perforation; therefore, limited sigmoidoscopy with minimal insufflation is appropriate for most patients. It has been found that patients with worse endoscopic scores have an increased likelihood of need for rescue therapy as well as increased need for colectomy compared to those who have a more favorable endoscopic scoring.[56]

CMV colitis can be found in up to one third of patients with acute severe ulcerative colitis refractory to steroid treatment.[57, 58] Risk factors for CMV colitis include severe medically refractory disease as well as receipt of steroid treatment and the presence of endoscopic ulceration (as CMV has preference for actively inflamed tissues).[59] Predictors of nonresponse to steroids are frequent bowel movements as well as elevated CRP and ESR, hypoalbuminemia, and colon dilatation.[56]

Pharmacotherapy

Sulfasalazine and 5-ASA have no role in treating acute severe ulcerative colitis or IBD-related toxic megacolon; these medications can only be started after the control of the severe acute disease.

Systemic intravenous (IV) steroids remain the mainstay of treatment for acute severe ulcerative colitis; treatment response to steroids should occur within 1 to 3 days. Dexamethasone had been shown to be effective in decreasing the expression of nitric oxide synthase.[8]  Either hydrocortisone 100 mg IV piggyback (IVPB) every 6 hours or methylprednisolone 60 mg IVPB every 24 hours is acceptable. Methylprednisolone is preferred due to its lower incidence of side effects (eg, sodium retention, potassium wasting) and its greater relative anti-inflammatory potency.

If a response to steroids is not seen, consider other rescue medical therapies, including infliximab or cyclosporine. In a study of 20 patients with severe ulcerative colitis without response to IV steroids, cyclosporine was superior to placebo in controlling the disease.[60]

The use of cyclosporine should be limited to patients not responding to steroids or are intolerant of these agents. Observational studies have confirmed the efficacy of infliximab in managing acute severe ulcerative colitis.[61, 62] In a randomized control trial that compared cyclosporine with infliximab in patients with acute severe ulcerative colitis resistant to intravenous steroids, the median time to response was similar between both groups, and there was no difference in the rate of mucosal healing or the need for surgery.[63] Therefore, the choice between cyclosporine and infliximab should be based on the provider's comfort level with using either drug. Patients whose condition fail to respond to immune modulators may not show improvement with cyclosporine; therefore infliximab may be a better option for these patients.[56]

Tacrolimus, a calcineurin inhibitor, has been also evaluated for the treatment of severe ulcerative colitis refractory to steroids. In one study, the clinical response was 50% with tacrolimus compared to 13% in the placebo group.[64]

Supportive care

While the patient is on medical therapy, daily assessment of their fluid balance and electrolytes as well as serial abdominal examinations should be pursued to rule out worsening of the disease and to monitor for complications such as perforation or an abscess.

Clostridium difficile colitis

Medical management is the initial recommended step in treating patients with severe fulminant C difficile colitis.

Initial medical management for severe C difficile infection is defined by a white blood cell (WBC) count above 15,000 cells/mL and/or a serum creatinine of at least 1.5 mg/dL; in this setting, vancomycin 125 mg orally 4 times a day for 10 days or fidaxomicin 200 mg orally twice a day for 10 days is recommended.[65]

Fulminant disease is defined by severe C difficile infection plus supportive data of hypotension, shock, ileus, or megacolon. It should be treated with vancomycin 500 mg orally or through a nasogastric (NG) tube and metronidazole 500 mg IV every 8 hours. If ileus is present, rectal vancomycin is recommended.[65]

Patients who have fulminant colitis that fails to respond to initial medical treatment should be considered as candidates for fecal transplantation. Studies have revealed that fecal transplantation is an effective treatment for critically ill patients with C difficile infection refractory to maximum medical therapy and who are not deemed to be surgical candidates.[40]

Additional therapies

Leukocytapheresis (LCAP) has been reported to be effective against toxic megacolon. In a series of six patients whose conditions failed to improve after treatment with antibiotics and high-dose steroids, toxic megacolon resolved in four patients by the morning after initiation of treatment with LCAP.[66] In the remaining two patients, toxic megacolon resolved approximately 40 hours later. Improvement continued in four of the six patients.[66]

Hyperbaric oxygen therapy has also been reported to be of use in the treatment of toxic,[67] but further studies are needed to confirm these results.

Shetler et al demonstrated that colonoscopic decompression and intracolonic vancomycin administration in the management of severe, acute, pseudomembranous colitis associated with ileus and toxic megacolon is feasible, safe, and effective in approximately 57-71% of these cases.[68]

IV immune globulin (IG) may potentially be a last-line adjunct therapy in patients with severe, complicated, refractory C difficile infection (eg, shock, ileus, megacolon), taking into account the possibility of adverse effects.[69]

Special patient populations

Patients infected with human immunodeficiency virus (HIV)

Careful management of HIV patients is recommended, with extensive work-up to rule out an infectious or inflammatory etiology for toxic megacolon. Early treatment for infections in HIV patients helps to lower mortality and morbidity in this subgroup of patients because the need for emergency laparotomy with subtotal colectomy and ileostomy is higher if treatment is delayed.[70, 71]

Pregnant women

It is always recommended that IBD be under remission before proceeding with pregnancy. If pregnant patients with ulcerative colitis develop severe fulminant colitis with toxic megacolon, high doses of IV steroids are recommended, and they are successful in 75% of the cases. Infliximab or urgent colectomy will be the solution for the remainder of gravid patients.[72, 73]

Surgical Care

Inflammatory bowel disease (IBD)

The procedure of choice for urgent colectomy is subtotal colectomy with end ileostomy for both ulcerative colitis and Crohn disease.[37]

Absolute indications for surgery in patients with acute, severe ulcerative colitis include the development of the following[74] :

Surgery should be considered in cases of acute severe colitis that fail to respond to steroid therapy within 3 to 5 days of treatment initiation. Delays in surgery can be associated with increased postoperative morbidity.[75]

If possible, optimize the patient's nutrition status before colectomy because poor nutritional status is associated with increased mortality and morbidity. Indications of poor nutritional status include the following[76, 77] :

Clostridium difficile colitis

Indications for surgical intervention in patients with severe C difficile colitis include the following:

Relative indications for surgery are severe leukocytosis with a white blood cell (WBC) count over 50,000 cells/mL and serum lactate levels above 5 mmol/L.

If surgical management is necessary for severely ill patients, perform subtotal colectomy with preservation of the rectum. Another option is a diverting loop ileostomy with colonic lavage, which has been associated with lower morbidity and mortality.

Medication Summary

Medications that may aid in controlling or treating toxic megacolon include corticosteroids, immunosuppressants, and/or immunomodulators. Antibiotics may be administered to prevent or treat infection.

Note that certain agents may exacerbate toxic megacolon, such as opioids, antidepressants, nonsteroidal anti-inflammatories, antidiarrheals, and anticholinergics.

Hydrocortisone (Solu-Cortef, Cortef)

Clinical Context:  Hydrocortisone decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Methylprednisolone (A-Methapred, Depo-Medrol, Medrol, Solu-Medrol)

Clinical Context:  Methylprednisolone decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

Class Summary

Corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids also modify the body's immune response to diverse stimuli.

Cyclosporine (Neoral, Gengraf, Sandimmune)

Clinical Context:  Cyclosporine is used in acute, severe ulcerative colitis that is refractory to IV corticosteroids. An 11-amino acid cyclic peptide and a natural product of fungi, it acts on T-cell replication and activity.

Cyclosporine is a specific modulator of T-cell function and an agent that depresses cell-mediated immune responses by inhibiting helper T-cell function. Preferential and reversible inhibition of T lymphocytes in the G0 or G1 phase of the cell cycle is suggested.

Cyclosporine binds to cyclophilin, an intracellular protein, which, in turn, prevents formation of interleukin-2 and the subsequent recruitment of activated T cells.

Cyclosporine has about 30% bioavailability, but there is marked interindividual variability. This agent specifically inhibits T-lymphocyte function, with minimal activity against B cells. Maximum suppression of T-lymphocyte proliferation requires that the drug be present during the first 24 hours of antigenic exposure.

Cyclosporine suppresses some humoral immunity and, to a greater extent, cell-mediated immune reactions (eg, delayed hypersensitivity, allograft rejection, experimental allergic encephalomyelitis, graft-vs-host disease) for a variety of organs.

Class Summary

Immunosuppressant agents inhibit immune reactions resulting from diverse stimuli.

Infliximab (Remicade)

Clinical Context:  Infliximab neutralizes the cytokine TNF-alpha and inhibits its binding to the TNF-alpha receptor. Mix in 250 mL normal saline for infusion over 2 hours. It must be used with a low-protein-binding filter (1.2 µm or less).

Class Summary

Immunomodulatory agents regulate immune reactions that are responsible for inflammation.

What is toxic megacolon?What conditions should be differentiated from toxic megacolon?What is the pathophysiology of toxic megacolon?What are inflammatory causes of toxic megacolon?What are infectious causes of toxic megacolon?What are other etiologies of toxic megacolon?Which factors increase the risk for toxic megacolon?What is the prevalence of toxic megacolon?What is the incidence of toxic megacolon in inflammatory bowel disease (IBD) and C difficile colitis?What is the prognosis of toxic megacolon?What should patient education about toxic megacolon include?What is the clinical presentation of toxic megacolon?What physical examination findings may be seen in toxic megacolon?What are peritoneal signs of perforation in toxic megacolon?What are the differential diagnoses for Toxic Megacolon?What should cause clinicians to suspect the diagnosis of toxic megacolon?What is the role of complete blood cell (CBC) count in the diagnosis of toxic megacolon?What are the roles of chemistry, nutrition, and coagulation panels in the workup of toxic megacolon?What is the role of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in the diagnosis of toxic megacolon?What are characteristic histologic findings of toxic megacolon?What is the role of radiography in the diagnosis of toxic megacolon?What radiographic findings are characteristic of toxic megacolon?What is the role of ultrasonography in the diagnosis of toxic megacolon?What is the role of endoscopy in the diagnosis of toxic megacolon?What is the role of computed tomography (CT) scanning in the diagnosis of toxic megacolon?What should be considered in the treatment of toxic megacolon?What is involved in the medical management of colitis and inflammatory bowel disease (IBD)?What is involved in the medical management of C difficile colitis?What are other potential medical therapies for treatment of toxic megacolon?Which special populations should considered in the treatment of toxic megacolon?What are indications for surgery in patients with inflammatory disease (IBD)-related colitis?What are indications for surgery in patients with C difficile colitis?What types of medications may be used in the treatment of toxic megacolon, and which agents should be avoided?Which medications in the drug class Immunomodulators are used in the treatment of Toxic Megacolon?Which medications in the drug class Immunosuppressant Agents are used in the treatment of Toxic Megacolon?Which medications in the drug class Corticosteroids are used in the treatment of Toxic Megacolon?

Author

Fadi Alali, MD, Fellow, Department of Gastroenterology, Ascension Providence Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Michael H Piper, MD, Clinical Assistant Professor, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine; Consulting Staff, Digestive Health Associates, PLC

Disclosure: Nothing to disclose.

Chief Editor

Burt Cagir, MD, FACS, Associate Regional Dean and Professor of Surgery, Geisinger Commonwealth School of Medicine; Director, General Surgery Residency Program, Executive Director, Donald Guthrie Foundation for Research and Education, Guthrie Robert Packer Hospital; Medical Director, Guthrie/RPH Skills and Simulation Lab; Associate in Surgery, Guthrie Robert Packer Hospital and Corning Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Brian Lin, New York College of Osteopathic Medicine

Disclosure: Nothing to disclose.

Clifford Y Ko, MD, MS, Professor, Department of Surgery, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Deepika Devuni, MD, Assistant Professor of Gastroenterology, University of Massachusetts Medical School

Disclosure: SIte PI for: Sequana Medical .

George Y Wu, MD, PhD, Professor, Department of Medicine, Director, Hepatology Section, Herman Lopata Chair in Hepatitis Research, University of Connecticut School of Medicine

Disclosure: Nothing to disclose.

Lisa M Rossi, MD, Fellow, Department of Gastroenterology-Hepatology, University of Connecticut School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Terence David Lewis, MBBS, FRACP, FRCPC, FACP Program Director, Internal Medicine Residency, & Assistant Chairman, Associate Professor, Department of Internal Medicine, Division of Gastroenterology, Loma Linda University Medical Center

Terence David Lewis, MBBS, FRACP, FRCPC, FACP is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Medical Association, California Medical Association, Royal College of Physicians and Surgeons of Canada, and Sigma Xi

Disclosure: Nothing to disclose.

Jerome H Liu, MD Staff Physician, Department of Surgery, University of California at Los Angeles Medical Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. Sheth SG, LaMont JT. Toxic megacolon. Lancet. 1998 Feb 14. 351(9101):509-13. [View Abstract]
  2. Marshak RH, Lester LJ. Megacolon a complication of ulcerative colitis. Gastroenterology. 1950 Dec. 16(4):768-72. [View Abstract]
  3. Moulin V, Dellon P, Laurent O, Aubry S, Lubrano J, Delabrousse E. Toxic megacolon in patients with severe acute colitis: computed tomographic features. Clin Imaging. 2011 Nov-Dec. 35(6):431-6. [View Abstract]
  4. Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis. 2012 Mar. 18(3):584-91. [View Abstract]
  5. Mostafazadeh B, Farzaneh E, Paeezi M, Nikkhah F. Toxic megacolon as a rare complication following atropine therapy due to organophosphate poisoning: A case report. Med Leg J. 2017 Dec. 85(4):221-3. [View Abstract]
  6. Khasanov R, Schaible T, Wessel LM, Hagl CI. The surgical treatment of toxic megacolon in Hirschsprung disease. Pediatr Emerg Care. 2016 Nov. 32(11):785-8. [View Abstract]
  7. Mourelle M, Casellas F, Guarner F, et al. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology. 1995 Nov. 109(5):1497-502. [View Abstract]
  8. Mourelle M, Vilaseca J, Guarner F, Salas A, Malagelada JR. Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. Am J Physiol. 1996 Mar. 270(3 pt 1):G425-30. [View Abstract]
  9. Guslandi M. Nitric oxide and inflammatory bowel diseases. Eur J Clin Invest. 1998 Nov. 28(11):904-7. [View Abstract]
  10. Schworer H, Bohn M, Waezsada SY, Raddatz D, Ramadori G. Successful treatment of megacolon associated with colitis with a nitric oxide synthase inhibitor. Am J Gastroenterol. 2001 Jul. 96(7):2273-4. [View Abstract]
  11. Kwok WC, Tam TCC, Lam DCL. First reported case of afatinib-associated toxic megacolon. Respirol Case Rep. 2018 Oct. 6(7):e00360. [View Abstract]
  12. Tariq S, Farooq A, Ali I, Wijesinghe H. Toxic colonoscopy--how investigating active inflammatory bowel disease can lead to the serious complication of toxic megacolon. BMJ Case Rep. 2015 Jul 22. 2015:[View Abstract]
  13. Roy MA. Inflammatory bowel disease. Surg Clin North Am. 1997 Dec. 77(6):1419-31. [View Abstract]
  14. Grieco MB, Bordan DL, Geiss AC, Beil AR Jr. Toxic megacolon complicating Crohn's colitis. Ann Surg. 1980 Jan. 191(1):75-80. [View Abstract]
  15. Chaudhuri A, Bekdash BA. Toxic megacolon due to Salmonella: a case report and review of the literature. Int J Colorectal Dis. 2002 Jul. 17(4):275-9. [View Abstract]
  16. McGuire E, Tiberi S, Ciesielczuk H, Melzer M. Shigellosis and toxic megacolon secondary to Shigella flexneri serotype 3a: The challenges of laboratory diagnosis. Int J Infect Dis. 2018 May. 70:104-6. [View Abstract]
  17. Kwok M, Maurice A, Lisec C, Brown J. Campylobacter colitis: Rare cause of toxic megacolon. Int J Surg Case Rep. 2016. 27:141-3. [View Abstract]
  18. Bartlett JG, Perl TM. The new Clostridium difficile--what does it mean?. N Engl J Med. 2005 Dec 8. 353(23):2503-5. [View Abstract]
  19. Arumilli BR, Koneru P, Fayyaz I. Toxic megacolon from hypervirulent Clostridium difficile infection (ribotype 027) following elective total knee replacement: an emerging challenge in modern health care. BMJ Case Rep. 2010. 2010:[View Abstract]
  20. Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc. 2010 Aug 16. 2(8):293-7. [View Abstract]
  21. McGregor A, Brown M, Thway K, Wright SG. Fulminant amoebic colitis following loperamide use. J Travel Med. 2007 Jan-Feb. 14(1):61-2. [View Abstract]
  22. Sidebotham EL, Sepkowitz K, Price AP, Steinherz PG, La Quaglia MP, Kayton ML. Eradication of cryptosporidium from a defunctionalized colon limb by refeeding stoma effluent. J Pediatr Surg. 2010 Jan. 45(1):E33-6. [View Abstract]
  23. Shimada Y, Iiai T, Okamoto H, et al. Toxic megacolon associated with cytomegalovirus infection in ulcerative colitis. J Gastroenterol. 2003. 38(11):1107-8. [View Abstract]
  24. Hung CW, Wu WF, Wu CL. Rotavirus gastroenteritis complicated with toxic megacolon. Acta Paediatr. 2009 Nov. 98(11):1850-2. [View Abstract]
  25. Mohite U, Kell J, Haj MA, et al. Invasive aspergillosis localised to the colon presenting as toxic megacolon. Eur J Haematol. 2007 Mar. 78(3):270-3. [View Abstract]
  26. Wodzinski MA, Snowden JA, Reilly JT. Toxic megacolon complicating chemotherapy for acute myeloid leukaemia. Postgrad Med J. 1994 Dec. 70(830):921-3. [View Abstract]
  27. Hayes-Lattin BM, Curtin PT, Fleming WH, et al. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis. Bone Marrow Transplant. 2002 Sep. 30(5):279-85. [View Abstract]
  28. Fitzgerald SC, Conlon S, Leen E, Walsh TN. Collagenous colitis as a possible cause of toxic megacolon. Ir J Med Sci. 2009 Mar. 178(1):115-7. [View Abstract]
  29. Bains S, Lloyd GM, Sutton CD, West K, Miller AS. A case of toxic megacolon in a patient with collagenous colitis. Tech Coloproctol. 2009 Jun. 13(2):165-6. [View Abstract]
  30. Umehara Y, Kudo M, Kawasaki M. Endoscopic findings of intestinal Behçet's disease complicated with toxic megacolon. Endoscopy. 2010. 42 Suppl 2:E173-4. [View Abstract]
  31. Adorian C, Khoury G, Tawil A, Sharara A. Behçet's disease complicated by toxic megacolon. Dig Dis Sci. 2003 Dec. 48(12):2366-8. [View Abstract]
  32. Atherton LD, Leib ES, Kaye MD. Toxic megacolon associated with methotrexate therapy. Gastroenterology. 1984 Jun. 86(6):1583-8. [View Abstract]
  33. Tschudin-Sutter S, Tamma PD, Naegeli AN, et al. Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. Clin Infect Dis. 2013 Dec. 57(12):1665-72. [View Abstract]
  34. Doshi R, Desai J, Shah Y, Decter D, Doshi S. Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States. Intern Emerg Med. 2018 Sep. 13(6):881-7. [View Abstract]
  35. Ciccocioppo R, Corazza GR. In-hospital mortality for toxic megacolon. Intern Emerg Med. 2018 Sep. 13(6):837-8. [View Abstract]
  36. Desai J, Elnaggar M, Hanfy AA, Doshi R. Toxic megacolon: background, pathophysiology, management challenges and solutions. Clin Exp Gastroenterol. 2020. 13:203-10. [View Abstract]
  37. Ausch C, Madoff RD, Gnant M, et al. Aetiology and surgical management of toxic megacolon. Colorectal Dis. 2006 Mar. 8(3):195-201. [View Abstract]
  38. Strauss RJ, Flint GW, Platt N, Levin L, Wise L. The surgical management of toxic dilatation of the colon: a report of 28 cases and review of the literature. Ann Surg. 1976 Dec. 184(6):682-8. [View Abstract]
  39. Ahmed N, Kuo YH. Early colectomy saves lives in toxic megacolon due to Clostridium difficile infection. South Med J. 2020 Jul. 113(7):345-9. [View Abstract]
  40. Cheng YW, Fischer M. Fecal microbiota transplantation: redefining surgical management of refractory Clostridium difficile infection. Clin Colon Rectal Surg. 2020 Mar. 33(2):92-7. [View Abstract]
  41. Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am. 1989 Mar. 18(1):73-82. [View Abstract]
  42. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci. 2010 Feb. 55(2):415-20. [View Abstract]
  43. Jalan KN, Sircus W, Card WI, et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology. 1969 Jul. 57(1):68-82. [View Abstract]
  44. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003 Nov. 98(11):2363-71. [View Abstract]
  45. Lee JC, Hung YP, Tsai BY, Tsai PJ, Ko WC. Severe Clostridium difficile infections in intensive care units: diverse clinical presentations. J Microbiol Immunol Infect. 2020 Aug 12. [View Abstract]
  46. Trudel JL, Deschenes M, Mayrand S, Barkun AN. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995 Oct. 38(10):1033-8. [View Abstract]
  47. Nwachuku E, Shan Y, Senthil-Kumar P, et al. Toxic Clostridioides (formerly Clostridium) difficile colitis: no longer a diarrhea associated infection. Am J Surg. 2021 Jan. 221(1):240-2. [View Abstract]
  48. Caprilli R, Vernia P, Colaneri O, Torsoli A. Blood pH: a test for assessment of severity in proctocolitis. Gut. 1976 Oct. 17(10):763-9. [View Abstract]
  49. Hokama A, Ohira T, Kishimoto K, Kinjo F, Fujita J. Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis. Intern Emerg Med. 2012 Oct. 7(5):487-8. [View Abstract]
  50. Maconi G, Sampietro GM, Ardizzone S, et al. Ultrasonographic detection of toxic megacolon in inflammatory bowel diseases. Dig Dis Sci. 2004 Jan. 49(1):138-42. [View Abstract]
  51. Imbriaco M, Balthazar EJ. Toxic megacolon: role of CT in evaluation and detection of complications. Clin Imaging. 2001 Sep-Oct. 25(5):349-54. [View Abstract]
  52. Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr (1988). 1991. 4 Suppl 1:S29-35. [View Abstract]
  53. Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology. 1980 Dec. 79(6):1199-204. [View Abstract]
  54. Present DH. Toxic megacolon. Med Clin North Am. 1993 Sep. 77(5):1129-48. [View Abstract]
  55. Panos MZ, Wood MJ, Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut. 1993 Dec. 34(12):1726-7. [View Abstract]
  56. [Guideline] Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar. 114(3):384-413. [View Abstract]
  57. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. Inflamm Bowel Dis. 2010 Sep. 16(9):1620-7. [View Abstract]
  58. Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Apr. 41(8):725-33. [View Abstract]
  59. McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015 Jan. 13(1):131-7; quiz e7. [View Abstract]
  60. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30. 330(26):1841-5. [View Abstract]
  61. Bressler B, Law JK, Al Nahdi Sheraisher N, et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol. 2008 Nov. 22(11):937-40. [View Abstract]
  62. Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. World J Gastroenterol. 2013 Feb 21. 19(7):1091-7. [View Abstract]
  63. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012 Dec 1. 380(9857):1909-15. [View Abstract]
  64. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012 May. 18(5):803-8. [View Abstract]
  65. [Guideline] McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and Children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19. 66(7):e1-e48. [View Abstract]
  66. Sawada K, Egashira A, Ohnishi K, et al. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci. 2005 Apr. 50(4):767-73. [View Abstract]
  67. Kuroki K, Masuda A, Uehara H, Kuroki A. A new treatment for toxic megacolon. Lancet. 1998 Sep 5. 352(9130):782. [View Abstract]
  68. Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc. 2001 Jul. 15(7):653-9. [View Abstract]
  69. Shah PJ, Vakil N, Kabakov A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Health Syst Pharm. 2015 Jun 15. 72(12):1013-9. [View Abstract]
  70. Beaugerie L, Ngo Y, Goujard F, et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. Gastroenterology. 1994 Sep. 107(3):858-63. [View Abstract]
  71. Davidson T, Allen-Mersh TG, Miles AJ, et al. Emergency laparotomy in patients with AIDS. Br J Surg. 1991 Aug. 78(8):924-6. [View Abstract]
  72. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978 Nov 18. 2(8099):1086-8. [View Abstract]
  73. Anderson JB, Turner GM, Williamson RC. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med. 1987 Aug. 80(8):492-4. [View Abstract]
  74. Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How?. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr. 32-33:71-8. [View Abstract]
  75. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010 Mar. 97(3):404-9. [View Abstract]
  76. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. 2009 Jun 7. 15(21):2570-8. [View Abstract]
  77. [Guideline] Lochs H, Dejong C, Hammarqvist F, et al, for the ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr. 2006 Apr. 25(2):260-74. [View Abstract]
  78. Khoury-Hanold W, Yordy B, Kong P, et al. Viral spread to enteric neurons links genital HSV-1 infection to toxic megacolon and lethality. Cell Host Microbe. 2016 Jun 8. 19(6):788-99. [View Abstract]
  79. Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilatation in ulcerative and Crohn's colitis. J Clin Gastroenterol. 1985 Apr. 7(2):137-43. [View Abstract]
  80. Grant CS, Dozois RR. Toxic megacolon: ultimate fate of patients after successful medical management. Am J Surg. 1984 Jan. 147(1):106-10. [View Abstract]
  81. Present DH, Wolfson D, Gelernt IM, et al. Medical decompression of toxic megacolon by "rolling." A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol. 1988 Oct. 10(5):485-90. [View Abstract]
  82. Actis GC, Ottobrelli A, Pera A, et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol. 1993 Jul. 17(1):10-3. [View Abstract]
  83. Sriram PV, Reddy KS, Rao GV, Santosh D, Reddy DN. Infliximab in the treatment of ulcerative colitis with toxic megacolon. Indian J Gastroenterol. 2004 Jan-Feb. 23(1):22-3. [View Abstract]
  84. van Geenen EJ, Sachar DB. Infliximab in Crohn's disease-associated toxic megacolon. J Clin Gastroenterol. 2012 Apr. 46(4):321-3. [View Abstract]
  85. Pascu M, Muller AR, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus in a patient with toxic megacolon. Int J Colorectal Dis. 2003 May. 18(3):271-5. [View Abstract]
  86. Tapani MJ, Olavi KH. Surgical management of toxic megacolon. Hepatogastroenterology. 2014 May. 61(131):638-41. [View Abstract]
  87. Heppell J, Farkouh E, Dube S, et al. Toxic megacolon. An analysis of 70 cases. Dis Colon Rectum. 1986 Dec. 29(12):789-92. [View Abstract]
  88. Lee EC, Truelove SC. Proctocolectomy for ulcerative colitis. World J Surg. 1980. 4(2):195-201. [View Abstract]
  89. Leppkes M, Ganslmayer M, Strauss R, Neurath MF. [Toxic megacolon] [German]. Med Klin Intensivmed Notfmed. 2015 Oct. 110(7):500-5. [View Abstract]
  90. Moura FA, de Andrade KQ, Dos Santos JC, Araujo OR, Goulart MO. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?. Redox Biol. 2015 Dec. 6:617-39. [View Abstract]
  91. Neumann H, Neurath MF, Atreya R. Endoscopic therapy in inflammatory bowel diseases. Viszeralmedizin. 2015 Aug. 31(4):280-6. [View Abstract]
  92. Siow VS, Bhatt R, Mollen KP. Management of acute severe ulcerative colitis in children. Semin Pediatr Surg. 2017 Dec. 26(6):367-72. [View Abstract]
  93. McConnie R, Kastl A. Clostridium difficile, colitis, and colonoscopy: pediatric perspective. Curr Gastroenterol Rep. 2017 Aug. 19(8):34. [View Abstract]
  94. Nayar DM, Vetrivel S, McElroy J, Pai P, Koerner RJ. Toxic megacolon complicating Escherichia coli O157 infection. J Infect. 2006 Apr. 52(4):e103-6. [View Abstract]

Toxic Megacolon. A 22-year-old man presented with abdominal pain, passage of blood and mucus per rectum, abdominal distention, fever, and disorientation. Findings from sigmoidoscopy confirmed ulcerative colitis. Abdominal radiographs obtained 2 days apart show mucosal edema and worsening of the distention in the transverse colon. The patient's clinical condition deteriorated over the next 36 hours despite steroid and antibiotic therapy, and the patient had to undergo a total colectomy and ileostomy.

Toxic Megacolon. Gross pathology specimen from a case of pseudomembranous colitis demonstrating characteristic yellowish plaques.

Toxic Megacolon. Computed tomography scan from a patient with pseudomembranous colitis demonstrating the classic accordion sign.

Toxic Megacolon. A 72-year-old woman presented with vomiting and abdominal distention. The supine (right) and erect (left) plain abdominal radiographs show gross dilatation of the colon with multiple air-fluid levels. On further questioning, the patient revealed that she was taking diuretics for hypertension. Blood biochemical tests revealed markedly lowered potassium levels. After potassium replacement therapy, the patient's pseudo-obstruction completely resolved.

Toxic Megacolon. A 22-year-old man presented with abdominal pain, passage of blood and mucus per rectum, abdominal distention, fever, and disorientation. Findings from sigmoidoscopy confirmed ulcerative colitis. Abdominal radiographs obtained 2 days apart show mucosal edema and worsening of the distention in the transverse colon. The patient's clinical condition deteriorated over the next 36 hours despite steroid and antibiotic therapy, and the patient had to undergo a total colectomy and ileostomy.

Toxic Megacolon. Plain abdominal radiograph from a patient with known ulcerative colitis who presented with an acute exacerbation of his symptoms. This image shows thumbprinting in the region of the splenic flexure of the colon.

Toxic Megacolon. A 45-year-old woman presented with acute pain and colitis of uncertain etiology. The radiograph shows an increase in gaseous distention of the distal transverse colon, now measuring up to 80 mm in diameter (it was 60 mm 2 days previous). The transverse colon and sigmoid colon are both featureless, consistent with severe colitis. There is fecal loading in the right side of colon. No evidence of free gas or pneumatosis intestinalis is noted. The appearance is concerning for toxic megacolon. Courtesy of Craig Hacking, MBBS, Associate Professor, Royal Brisbane and Women’s Hospital (Radiopaedia.org, rID: 79194).

Toxic Megacolon. Computed tomography scan from a patient with pseudomembranous colitis demonstrating the classic accordion sign.

Toxic Megacolon. A 22-year-old man presented with abdominal pain, passage of blood and mucus per rectum, abdominal distention, fever, and disorientation. Findings from sigmoidoscopy confirmed ulcerative colitis. Abdominal radiographs obtained 2 days apart show mucosal edema and worsening of the distention in the transverse colon. The patient's clinical condition deteriorated over the next 36 hours despite steroid and antibiotic therapy, and the patient had to undergo a total colectomy and ileostomy.

Toxic Megacolon. A 72-year-old woman presented with vomiting and abdominal distention. The supine (right) and erect (left) plain abdominal radiographs show gross dilatation of the colon with multiple air-fluid levels. On further questioning, the patient revealed that she was taking diuretics for hypertension. Blood biochemical tests revealed markedly lowered potassium levels. After potassium replacement therapy, the patient's pseudo-obstruction completely resolved.

Toxic Megacolon. Gross pathology specimen from a case of pseudomembranous colitis demonstrating characteristic yellowish plaques.

Toxic Megacolon. Computed tomography scan from a patient with pseudomembranous colitis demonstrating the classic accordion sign.

Toxic Megacolon. Plain abdominal radiograph from a patient with known ulcerative colitis who presented with an acute exacerbation of his symptoms. This image shows thumbprinting in the region of the splenic flexure of the colon.

Toxic Megacolon. Increased postrectal space is a known feature of ulcerative colitis.

Toxic Megacolon. A 45-year-old woman presented with acute pain and colitis of uncertain etiology. The radiograph shows an increase in gaseous distention of the distal transverse colon, now measuring up to 80 mm in diameter (it was 60 mm 2 days previous). The transverse colon and sigmoid colon are both featureless, consistent with severe colitis. There is fecal loading in the right side of colon. No evidence of free gas or pneumatosis intestinalis is noted. The appearance is concerning for toxic megacolon. Courtesy of Craig Hacking, MBBS, Associate Professor, Royal Brisbane and Women’s Hospital (Radiopaedia.org, rID: 79194).